Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Nanexa via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
2023-12-20 08:00:00
Nanexa AB today announces that the Clinical Trial Application for the Phase I study of NEX-22 in patients with type 2 diabetes has been received and validated by the European Medicines Agency (EMA).
"EMA has now made its validation of the application as a first step and Nanexa is entering the process where we are expected to answer questions on the documentation and data that form the basis of the application. Our goal is to be able to start the Phase I study based on an approval in the first quarter of 2024, which we really look forward to", says David Westberg, CEO of Nanexa.